Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma.

Details

Request a copyRequest a copy
Serval ID
serval:BIB_676BFC958B41
Type
Inproceedings: an article in a conference proceedings.
Publication sub-type
Abstract (Abstract): shot summary in a article that contain essentials elements presented during a scientific conference, lecture or from a poster.
Collection
Publications
Institution
Production externe
Title
Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma.
Title of the conference
Journal of Clinical Oncology
Author(s)
Leleu Xavier, Mateos Maria-Victoria, Jagannath Sundar, Delimpasi Sosana, Simonova Maryana, Spicka Ivan, Pour Luděk, Kriachok Iryna, Gavriatopoulou Maria, Dimopoulos Meletios A., Pylypenko Halyna, Auner Holger W., Reuben Benjamin, Venner Christopher P., Garg Mamta, DeCastro Andrew, Shah Jatin J., Grosicki Sebastian, Richardson Paul G.
Publisher
American Society of Clinical Oncology (ASCO)
Organization
Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Address
ELECTR NETWORK
ISSN
0732-183X
1527-7755
Publication state
Published
Issued date
20/05/2021
Volume
39
Number
15_suppl
Pages
8024-8024
Language
english
DOI
10.1200/jco.2021.39.15_suppl.8024
Web of science
000708120604187
Create date
02/12/2024 17:49
Last modification date
04/12/2024 8:07
Usage data